黄酮类化合物逆转肿瘤多药耐药作用的研究进展  

Research progress on reversal of multidrug resistance in tumors by flavonoids

作　　者：金焕 谭爱萍[1] 刘克辛 JIN Huan;TAN Aiping;LIU Kexin(Department of Pharmacy,the First Affiliated Hospital of Dalian Medical University,Dalian 116044,China;Department of Clinical Pharmacology,College of Pharmacy,Dalian Medical University,Dalian 116044,China)

机构地区：[1]大连医科大学附属第一医院药学部,辽宁大连116044 [2]大连医科大学药学院临床药理教研室,辽宁大连116044

出　　处：《药物评价研究》2018年第6期945-951,共7页Drug Evaluation Research

基　　金：国家自然科学基金资助项目(81473280);辽宁省自然科学基金资助项目(20170540293)

摘　　要：肿瘤多药耐药是肿瘤治疗过程中一个亟待解决的难题,其表现为肿瘤细胞对单一或多种化疗药物同时出现耐药性,从而导致治疗失败,与药物的化学结构和作用机制无关。将化疗药物与肿瘤多药耐药逆转剂联合应用是目前公认的治疗方案之一。黄酮类化合物由于其低毒、高效,具有多种药理作用等优点而受到广泛的关注。在肿瘤治疗期间,黄酮类化合物能通过抑制ABC转运体、诱导凋亡、调节氧化应激等作用逆转肿瘤多药耐药。归纳总结了黄酮类化合物逆转肿瘤多药耐药的主要机制、应用及其纳米剂型改造的进展,为进一步的临床研究提供参考。Trumor multidrug resistance（MDR） is a problem that needs to be solved in the course of tumor treatment. MDR is characterized by the simultaneous emergence of resistance to single or multiple chemotherapeutic drugs in tumor cells resulting in treatment failure, regardless of the chemical structure and mechanism of the drug. Combining chemotherapeutic agents with MDR reversal agents is currently recognized as one of the treatment options. Flavonoids have received extensive attention because of their low toxicity, high efficiency, and their many pharmacological effects. During the treatment of tumors, flavonoids can reverse MDR by inhibiting ABC transporter, inducing apoptosis and regulating oxidative stress. This article summarizes the main mechanisms of flavonoids on reversal MDR and the progress of the modification of nano-formulations, in order to provide reference for further clinical research.

关 键 词：肿瘤治疗 多药耐药 黄酮类化合物 药物转运体 

分 类 号：R962.2[医药卫生—药理学]